XNAS · AMGN

-0.12% · -$0.5400 · Vol Not reported

Pre-market · updated 07:24:58 ET

Amgen Inc

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

$442.30

Card

Relationship Map

Veridion Score

BETAHIGH CONF · 6 of 6 factors measured

Wed Sep 2 · last completed session · Pre-market · regular session opens 9:30 ET · AMGN

Methodology

AMGN

Amgen Inc

Wed Sep 2 · last completed session · Pre-market · regular session opens 9:30 ET

72/100

Upper range

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

72/ 100

Veridion Score

Upper range · HIGH confidence

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: HIGH · 6 of 6 factors measured · Wed Sep 2 · last completed session · Pre-market · regular session opens 9:30 ET

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is AMGN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move AMGN next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress / Form 4

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Aug 13
Form 4Checking access
Khosla Rachna Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Aug 12
CongressChecking access
Sheldon Whitehouse sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Aug 7
Form 4Checking access
Miller Derek Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Aug 7
Form 4Checking access
Grygiel Nancy A. Form 4 sale
Checking the receipt access included with your plan.
SEC Form 4Checking access
Jul 20
CongressChecking access
Ro Khanna sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jul 8
CongressChecking access
Ro Khanna purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jun 30
CongressChecking access
Ro Khanna purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jun 16
CongressChecking access
Ro Khanna purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jun 5
CongressChecking access
David J. Taylor purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Jun 2
CongressChecking access
Ro Khanna purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access

About Amgen Inc

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Listed since

1983

Employees

32K

Country

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$442.84

Last session

Day high

$442.84

Last session

Day low

$442.84

Last session

Previous close

$442.84

52W high

$443.84

-0.35% from high

52W low

$271.18

99% of range

Market cap

$239.4B

P/E

27.15×

EPS

$16.29

Beta

0.20

Shares out

540.6M

Avg volume

2.6M

VWAP

$442.84

Last session

Price history computed in-house

+1.22%

+13.40%

+26.52%

+55.82%

YTD

+35.13%

SMA 50 $393.52 · above

SMA 200 $357.43 · above

52W position 99%

AMGN overview

Veridion Score

Registered · 2026-09-02

6 of 6 factors measured

Latest receipt rows

Sheldon Whitehouse · Sale

13F holders

None on file

Relationship mapTrace receipt-backed holders and filings around AMGN.Congress disclosuresOpen receipt and filing context for AMGN.MethodologyReview score inputs, coverage rules, and limitations.

SEC Form 4 ledger

AMGN insider activity

Amgen Inc

Score

72 · Upper range

Pressure

Net selling

Filings

Buys / sells

0 / 6

Net value

-$4.1M

Insiders

Named filers

Khosla Rachna

SVP, Business Development

Leadership

Miller Derek

SVP, Human Resources

Leadership

Grygiel Nancy A.

SVP & CCO

Leadership

Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Net selling: -$4.1M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Scroll across filed transactions. Filing date stays visible.

Filing date	Trade date	Insider	Title	Type	Price	Qty	Owned	Value	Receipt
2026-08-13	2026-08-13	Khosla Rachna	SVP, Business Development	sell	$416.43	1,252	6,404	$521K	SEC Form 4
2026-08-13	2026-08-11	Khosla Rachna	SVP, Business Development	sell	$412.57	2,000	6,404	$825K	SEC Form 4
2026-08-07	2026-08-06	Miller Derek	SVP, Human Resources	sell	$402.54	2,069	12,462	$833K	SEC Form 4